Palatin Technologies Has Started Patient Dosing In Phase 2 Study Of Bremelanotide Co-administered With Tirzepatide For Obesity, Complete Enrollment Is Currently Expected In 3Q 2024, With Topline Data Expected In Q1 Calendar Year 2025
Palatin Technologies已经开始对肥胖病患进行第2阶段研究,使用Bremelanotide与Tirzepatide联合治疗,预计将于2024年第3季度完成招募,预计在2025年第1季度公布头条数据